fulvestrant

{
  "id": "MLC-T-ONC-003358",
  "term": "fulvestrant",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat certain types of breast cancer. It is used alone or with ribociclib succinate in postmenopausal women who have not been treated with hormone therapy or whose disease got worse after treatment with hormone therapy. It is also used with palbociclib or abemaciclib in women whose disease got worse after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Fulvestrant binds to proteins called estrogen receptors, which are found in some breast cancer cells. These proteins may cause cancer cells to grow. Fulvestrant blocks these proteins and may keep cancer cells from growing. It is a type of antiestrogen. Also called Faslodex and ICI 182780.",
    "A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines."
  ],
  "synonyms": [
    "Faslodex",
    "ICI 182780"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/fulvestrant/"
}